Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.

Trial Details

NCT ID
NCT06815497
Phase
PHASE2
Sponsor
Tyler J Curiel
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Telmisartan
Locations (sample)
  • Lebanon, New Hampshire, United States|43.64229,-72.25176
  • Manchester, New Hampshire, United States|42.99564,-71.45479

Key Eligibility Criteria

  • ≥18 years of age
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
  • Able and willing to provide informed consent.
  • Histologically proven high-grade serous ovarian carcinomas (HGSOC)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →